Adiposity and Endothelin Receptor Function

• Status: Recruiting
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Augusta University
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• If you are an adult between the ages of 18-40 year old

Exclusion Criteria:

• Evidence of cardiovascular, pulmonary, renal, hepatic, cerebral, or metabolic disease

• Evidence of pregnancy

• Using medications that affect vascular tone (i.e., nitrates, etc.)

• Use of any anticoagulants (i.e. aspirin)

• Anemia

• If you are postmenopausal

• If you have uncontrolled hypertension (treated resting SBP >140 mm Hg or DBP >90 mm Hg)